Advisory Board November 30, 2022
In a new study published in the New England Journal of Medicine, lecanemab, an experimental Alzheimer’s drug developed by Eisai and Biogen, produced “moderately less decline on measures of cognition and function” compared to those receiving a placebo—but the authors concluded more research is needed to “determine the efficacy and safety” of the drug.
Study details
Similar to Aduhelm, lecanemab reduces abnormal clumps of beta amyloid in patients’ brains, proteins that are typically a sign of Alzheimer’s disease.
For the study, 1,795 patients with mild cognitive impairment caused by Alzheimer’s disease, or early-stage Alzheimer’s, were enrolled. Among the participants, 898 were given lecanemab and 897 were given a placebo over the course of 18 months.
The patients were then tested...
Today's Sponsors
Today's Sponsor